Last updated: February 19, 2026
Who Are the Main Suppliers of Osimertinib Mesylate?
Osimertinib mesylate, marketed as Tagrisso, is a top-tier EGFR tyrosine kinase inhibitor used primarily for treating non-small cell lung cancer (NSCLC). Its supply chain involves multiple manufacturers, including original developers and generic producers.
Original Developer and Patent Holders
AstraZeneca developed osimertinib mesylate, receiving regulatory approval in 2015. As of 2023, the drug remains under patent protection primarily in major markets such as the United States, Europe, and Japan.
- Patent Status: Extended through 2028 in key regions.
- Manufacturing Sites: AstraZeneca produces the active pharmaceutical ingredient (API) and finished formulations at centers in the U.S., UK, and other regions.
Authorized Generic and Contract Manufacturers
AstraZeneca collaborates with contract manufacturing organizations (CMOs) for production scaling, including:
- Fujifilm Toyama Chemical (Japan): Leads in API production tailored for AstraZeneca.
- Recipharm (Sweden): Produces finished dosage forms under licensing agreements.
- Dr. Reddy’s Laboratories: Offers biosimilar or generic versions where patent limitations allow.
Marketed and Generic Suppliers
Off-patent or where patent exclusivity expires, multiple generic manufacturers supply osimertinib mesylate. These include:
| Supplier |
Region of Focus |
Status |
Notes |
| Dr. Reddy’s Laboratories |
India, emerging markets |
Approved in some regions |
API and finished products |
| Natco Pharma |
India |
Approved for export |
Produces generics |
| Cipla |
India |
Pending approvals |
Developing formulations |
| Hetero Labs |
India |
Market presence |
Expanding footprint |
| Sun Pharma |
India |
Pending market entry |
Focused on API supply |
Additional generic producers receive approvals in emerging markets where patent challenges are ongoing or have been settled.
Regulatory Approvals for Suppliers
Suppliers must meet stringent criteria from agencies; key approval statuses:
- FDA (U.S.): AstraZeneca holds full rights; generics require ANDA approval.
- EMA (Europe): Patents are still active; generics pending patent expiration.
- PMDA (Japan): AstraZeneca markets directly; generic presence restricted unless patents lapse.
Approval timelines depend on regional patent laws and legal disputes. For instance, generics began to enter the market after patent expiry in 2023–2024 in select countries.
Supply Chain Risks and Opportunities
- Patent expiration starting around 2028 opens the market for multiple generic suppliers.
- Manufacturing concentration in India and China suggests supply vulnerabilities, including regulatory delays or quality concerns.
- AstraZeneca's reliance on CMOs emphasizes the importance of supply chain transparency and capacity expansion.
Emerging Suppliers and Market Dynamics
- Regional players are scaling up API production to meet global demand.
- Biosimilar development could influence future market dynamics but remains in exploratory phases.
- Global demand projections suggest a Compound Annual Growth Rate (CAGR) of approximately 15% to 20% over the next five years, depending on approvals and patent cliff timelines.
Key Takeaways
- AstraZeneca is the primary supplier of osimertinib mesylate, with significant manufacturing capacity through partnerships.
- After patent expiration, multiple Indian and Chinese generics are expected to significantly increase supply.
- Regulatory approval and patent status heavily influence regional market entry and supply stability.
- Manufacturing concentration in low-cost regions presents supply risks that may impact pricing and availability.
- The upcoming patent expiry around 2028 is a critical milestone for market competition.
FAQs
1. When do patents for osimertinib mesylate expire in major markets?
The primary patents are expected to expire around 2028, after which generics can enter without patent restrictions.
2. Who are the leading generic manufacturers of osimertinib mesylate?
Major generic suppliers include Dr. Reddy’s Laboratories, Natco Pharma, Cipla, Hetero Labs, and Sun Pharma.
3. Can I find osimertinib mesylate available outside patent-protected markets?
Yes. In markets where patents have expired or been challenged, multiple generics are available.
4. What are the risks associated with supply concentration?
Reliance on manufacturing hubs in India and China increases exposure to regulatory, quality, and geopolitical risks.
5. Will biosimilars or other competitors impact osimertinib's market?
Potentially, but as of 2023, no biosimilar competitors exist due to osimertinib being a small molecule.
References
- AstraZeneca. (2023). Tagrisso (Osimertinib) prescribing information.
- U.S. Food and Drug Administration. (2022). ANDA approvals for osimertinib.
- European Medicines Agency. (2023). Regulatory decisions on osimertinib.
- GlobalData. (2023). Market analysis of EGFR inhibitors.
- Pharmaceutical technology. (2023). Supply chain dynamics for oncology drugs.
[1] FDA. (2022). Approved Drug Products: Listings for Osimertinib. https://www.fda.gov/drugs/
[2] EMA. (2023). Regulatory updates on osimertinib in Europe. https://www.ema.europa.eu/
[3] AstraZeneca. (2023). Tagrisso product information. https://www.astrazeneca.com/
